No black box warning on record for Dermoscribe Seborrheic Dermatitis
As of the latest FDA labeling reviewed, Dermoscribe Seborrheic Dermatitis (SULFUR, SALICYLIC ACID, HYDROCORTISONE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Dermoscribe Seborrheic Dermatitis medicine page for the complete safety profile.